P-696 HUNTING FOR HYPERTENSION GENES: THE NATIONAL MILLENNIUM PROJECT IN JAPAN
Yasuharu Tabara, Katsuhiko Kohara, Jun Nakura, Tetsuro Miki, The study Group of Millennium Genome Project for Hypertension. Medical Genetics, Ehime University School of Medicine, Toon, Ehime, Japan; Geriatric Medicine, Ehime University School of Medicine, Toon, Ehime, Japan. In 2000, national cooperative projects, under the banner of "Millennium Projects", were started in Japan. The projects are focusing on bold technological innovations in three areas which are of vital importance to Japan: informatization, the aging society and the environment. The identification of genetic variations linked to the development of hypertension is one of the leading missions of the Millennium Project. Four other diseases; diabetes mellitus, cancer, asthma, and Alzheimer's disease, were also targets for the gene hunting. This is the 2nd interim report of the Millennium Projects, division of hypertension gene researching.
The whole-genome case-control analyses, using 100,000 SNP markers, have been performed as a 1st screening. The SNPs were selected from the JSNP database, a database of SNPs in Japanese (http:// snp.ims.u-tokyo.ac.jp/). The case subjects (nϭ188) fulfilling the following criteria were recruited from Japan nationwide: male, BMI Ͻϭ 25 kg/m 2 , SBP ϭϾ 160 mmHg and/or DBP ϭϾ 100 mmHg or under untihypertensive treatment, age of onset was between 30 and 59 (y.o.), and having family history of hypertension within parents and siblings. The contrastive patients with other four diseases were served as the normotensive subjects (nϭ752). In the first-screening, 21,602 SNPs showed probability values less than 0.05 in the 2X2 and/or 2X3 chisquared analyses. In the 2nd screening, 1,800 SNPs were analyzed in other 752 hypertensive cases and 752 normotensive controls, and 212 SNPs remained statistically significant. To further clarify the susceptible SNPs, 3rd screening was carried out using other case-control (619/1,406) subjects. Of 212 SNPs, 4 SNPs showed probability values less than 0.05 (0.003 to 0.035) in the comparison of allele frequency. The odds ratios of these SNPs were between 1.18 and 1.23 in the allelic model.
To further narrow the susceptible loci and to identify the tag-SNPs, the haplotype analysis is now carrying on. The validity of these tag-SNPs will be verified using the 12,000 population samples.
Key Words: The National Millennium Project in Japan, Whole genome screening
P-697 NITRATES MAY ATTENUATE BLOOD PRESSURE LOWERING BY STATINS
Hiroaki Kawano, Katsusuke Yano. Department of Cardiovascular Medicine, Nagasaki University, Nagasaki, Nagasaki, Japan.
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have pleiotropic effects that may contribute to their favorable clinical results. Recent studies have shown that statins can reduce blood pressure (BP) significantly. It has been suggested that statins improve NO-mediated endothelial function. To assess the effect of statin on blood pressure via NO, we examined the blood pressure change before and after the treatment with statins in patients with or without nitrates (N). Seventy-one consecutive patients with hyperlipidemia and hypertension who had already treated with anti-hypertensive agents at least for one year (male 31 patients, female 40 patients, age 37ϳ78 years, mean age 63ϩ10 years) participated in this study. We compared the blood pressure change in these patients treated with statins for 6 months (pravastatin 45 patients, simvastatin 19, fluvastatin 7). Anti-hypertensive agents were not changed during this study. These patients were divided into two groups; N (ϩ) (21 patients), and N (-) (50 patients), and we also compared the blood pressure change in these groups. Statistical analysis was performed by paired t-test.
Results: In all patients in this study, systolic BP (SBP) (136 ϩ 17 to 130 ϩ/-13mmHg, PϽ0.0001) and diastolic BP (DBP) (79 ϩ/-11 to 76 ϩ/-9 mmHg, PϽ0.0001)were significantly lowered by statin treatment as well as LDL-C (171 ϩ 28 to 125 ϩ 20 mg/dl, PϽ0.0001). In N (-) group, SBP (137 ϩ/-18 to 129 ϩ/-13mmHg, PϽ0.0001), DBP (79 ϩ 12 to 76 ϩ 10mmHg, PϽ0.05), and LDL-C (172 ϩ/-28 to 132 ϩ/-24 mg/dl, PϽ0.0001) were also significantly lowered. However, there was no significant changes of SBP (134 ϩ/-16 to 132 ϩ/-14mmHg, n.s) and DBP (78 ϩ/-10 to 77 ϩ/-6 mmHg, n.s.) in N (ϩ) group although LDL-C (174 ϩ/-26 to 126 ϩ/-18 mg/dl, PϽ0.0001) were significantly lowered. In conclusion, the results of this study suggest that the additional blood pressure reduction observed in patients treated with statins may be related to NO system. 
